Zuellig Pharma Launches Lilly’s Innovative Obesity and Diabetes Medicine in Thailand
- Written by Telegraph Magazine

Mounjaro® (tirzepatide) will be available in the market from the end of May 2025
BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro® (tirzepatide), the innovative obesity and diabetes medicine developed by Eli Lilly and Company, will be launched in Thailand at the end of May 2025.Read more: Zuellig Pharma Launches Lilly’s Innovative Obesity and Diabetes Medicine in Thailand